NeuroSense's PrimeC Gains Momentum in ALS Drug Pipeline NeuroSense Therapeutics is advancing PrimeC, a combination therapy for ALS, through regulatory pathways. With Orphan Drug Designation, the therapy targets multiple mechanisms of ALS. A Phase 3 trial is planned for 2025, with Canadian market approval potentially following in early 2026.23